Cadrenal Therapeutics Inc (CVKD) USD0.001

Sell:$15.40Buy:$17.10$0.65 (3.86%)

Prices delayed by at least 15 minutes
Sell:$15.40
Buy:$17.10
Change:$0.65 (3.86%)
Prices delayed by at least 15 minutes
Sell:$15.40
Buy:$17.10
Change:$0.65 (3.86%)
Prices delayed by at least 15 minutes

Company Information

About this company

Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions. Tecarfarin has orphan drug and fast track designations from the United States Food and Drug Administration for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). It is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with left ventricular assist devices (LVADs) and those with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the commonly prescribed Vitamin K Antagonist (warfarin).

Key people

Quang Pham
Chairman of the Board, Chief Executive Officer
Matthew K. Szot
Chief Financial Officer
Jeffrey Cole
Chief Operating Officer
James J. Ferguson
Chief Medical Officer
Robert Lisicki
Independent Director
John R. Murphy
Independent Director
Glynn Wilson
Independent Director
Steven Zelenkofske
Independent Director
Click to see more

Key facts

  • EPIC
    CVKD
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US1276362076
  • Market cap
    $33.21m
  • Employees
    4
  • Shares in issue
    1.88m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.